Crescent Biopharma Inc (Pre-Reincorporation)
NASDAQ:CBIO
Income Statement
Earnings Waterfall
Crescent Biopharma Inc (Pre-Reincorporation)
Income Statement
Crescent Biopharma Inc (Pre-Reincorporation)
| Dec-2013 | Mar-2014 | Jun-2014 | Sep-2014 | Dec-2014 | Mar-2015 | Jun-2015 | Sep-2015 | Dec-2015 | Mar-2016 | Jun-2016 | Sep-2016 | Dec-2016 | Mar-2017 | Jun-2017 | Sep-2017 | Dec-2017 | Mar-2018 | Jun-2018 | Sep-2018 | Dec-2018 | Mar-2019 | Jun-2019 | Sep-2019 | Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||||||||||||||||||||||||||||||||||||||||
| Revenue |
4
N/A
|
0
-95%
|
15
+7 879%
|
15
0%
|
15
-1%
|
15
N/A
|
20
+33%
|
20
N/A
|
20
+0%
|
20
+0%
|
0
-100%
|
0
+50%
|
0
-67%
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
9
N/A
|
9
N/A
|
10
+11%
|
10
+2%
|
2
-78%
|
2
N/A
|
1
-41%
|
1
-11%
|
0
-91%
|
0
+73%
|
0
-47%
|
0
-20%
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
|
| Operating Income | ||||||||||||||||||||||||||||||||||||||||||||||
| Operating Expenses |
(15)
|
(16)
|
(20)
|
(23)
|
(26)
|
(28)
|
(31)
|
(31)
|
(33)
|
(33)
|
(32)
|
(33)
|
(32)
|
(32)
|
(32)
|
(33)
|
(34)
|
(38)
|
(42)
|
(46)
|
(52)
|
(55)
|
(59)
|
(61)
|
(61)
|
(63)
|
(61)
|
(61)
|
(62)
|
(60)
|
(60)
|
(63)
|
(65)
|
(64)
|
(63)
|
(54)
|
(47)
|
(44)
|
(39)
|
(40)
|
(39)
|
(39)
|
(41)
|
(37)
|
(33)
|
|
| Selling, General & Administrative |
(3)
|
(4)
|
(4)
|
(5)
|
(7)
|
(7)
|
(7)
|
(8)
|
(8)
|
(8)
|
(8)
|
(8)
|
(9)
|
(9)
|
(9)
|
(9)
|
(10)
|
(11)
|
(11)
|
(11)
|
(11)
|
(12)
|
(13)
|
(13)
|
(14)
|
(15)
|
(16)
|
(17)
|
(17)
|
(16)
|
(17)
|
(17)
|
(17)
|
(18)
|
(19)
|
(19)
|
(19)
|
(20)
|
(19)
|
(20)
|
(19)
|
(19)
|
(18)
|
(17)
|
(18)
|
|
| Research & Development |
(12)
|
(13)
|
(15)
|
(17)
|
(20)
|
(21)
|
(23)
|
(23)
|
(25)
|
(25)
|
(23)
|
(24)
|
(23)
|
(24)
|
(24)
|
(23)
|
(24)
|
(27)
|
(31)
|
(35)
|
(40)
|
(43)
|
(47)
|
(48)
|
(47)
|
(48)
|
(45)
|
(45)
|
(45)
|
(43)
|
(44)
|
(46)
|
(47)
|
(46)
|
(44)
|
(35)
|
(28)
|
(24)
|
(20)
|
(21)
|
(20)
|
(21)
|
(23)
|
(19)
|
(14)
|
|
| Operating Income |
(11)
N/A
|
(16)
-52%
|
(5)
+71%
|
(8)
-65%
|
(11)
-46%
|
(13)
-18%
|
(11)
+18%
|
(11)
-4%
|
(13)
-13%
|
(13)
-4%
|
(32)
-139%
|
(32)
-2%
|
(32)
+2%
|
(32)
-1%
|
(32)
0%
|
(33)
-1%
|
(34)
-4%
|
(38)
-12%
|
(42)
-10%
|
(46)
-10%
|
(52)
-12%
|
(55)
-6%
|
(59)
-9%
|
(61)
-3%
|
(61)
-1%
|
(54)
+11%
|
(52)
+5%
|
(51)
+1%
|
(52)
0%
|
(58)
-12%
|
(58)
-1%
|
(62)
-6%
|
(63)
-3%
|
(64)
-1%
|
(63)
+2%
|
(54)
+14%
|
(47)
+13%
|
(44)
+8%
|
(39)
+10%
|
(40)
-3%
|
(39)
+3%
|
(39)
0%
|
(41)
-4%
|
(37)
+10%
|
(33)
+12%
|
|
| Pre-Tax Income | ||||||||||||||||||||||||||||||||||||||||||||||
| Interest Income Expense |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
2
|
2
|
3
|
4
|
4
|
4
|
4
|
3
|
2
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
2
|
2
|
2
|
2
|
2
|
1
|
1
|
|
| Non-Reccuring Items |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(6)
|
(8)
|
|
| Gain/Loss on Disposition of Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
|
| Pre-Tax Income |
(11)
N/A
|
(16)
-52%
|
(5)
+72%
|
(8)
-65%
|
(11)
-47%
|
(13)
-18%
|
(11)
+18%
|
(11)
-4%
|
(13)
-13%
|
(13)
-3%
|
(32)
-140%
|
(32)
-2%
|
(32)
+2%
|
(32)
-1%
|
(32)
0%
|
(32)
0%
|
(33)
-3%
|
(37)
-11%
|
(40)
-9%
|
(44)
-9%
|
(48)
-11%
|
(51)
-5%
|
(55)
-9%
|
(57)
-3%
|
(58)
-1%
|
(51)
+11%
|
(50)
+3%
|
(50)
-1%
|
(51)
-2%
|
(58)
-13%
|
(58)
-1%
|
(62)
-6%
|
(63)
-3%
|
(64)
-1%
|
(63)
+2%
|
(54)
+14%
|
(47)
+13%
|
(42)
+9%
|
(37)
+12%
|
(38)
-2%
|
(37)
+3%
|
(37)
-1%
|
(39)
-5%
|
(40)
-2%
|
(38)
+5%
|
|
| Net Income | ||||||||||||||||||||||||||||||||||||||||||||||
| Tax Provision |
0
|
0
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Income from Continuing Operations |
(11)
|
(16)
|
(5)
|
(8)
|
(11)
|
(13)
|
(11)
|
(11)
|
(13)
|
(13)
|
(32)
|
(32)
|
(32)
|
(32)
|
(32)
|
(32)
|
(33)
|
(37)
|
(40)
|
(44)
|
(48)
|
(51)
|
(55)
|
(57)
|
(58)
|
(51)
|
(50)
|
(50)
|
(51)
|
(58)
|
(58)
|
(62)
|
(63)
|
(64)
|
(63)
|
(54)
|
(47)
|
(42)
|
(37)
|
(38)
|
(37)
|
(37)
|
(39)
|
(40)
|
(38)
|
|
| Net Income (Common) |
(11)
N/A
|
(16)
-52%
|
(5)
+71%
|
(8)
-62%
|
(11)
-46%
|
(13)
-18%
|
(11)
+18%
|
(11)
-5%
|
(13)
-13%
|
(13)
-3%
|
(32)
-140%
|
(32)
-2%
|
(32)
+2%
|
(32)
-1%
|
(32)
0%
|
(32)
0%
|
(33)
-3%
|
(37)
-11%
|
(40)
-9%
|
(44)
-9%
|
(48)
-11%
|
(51)
-5%
|
(55)
-9%
|
(57)
-3%
|
(58)
-1%
|
(51)
+11%
|
(50)
+3%
|
(50)
-1%
|
(51)
-2%
|
(58)
-13%
|
(58)
-1%
|
(62)
-6%
|
(63)
-3%
|
(64)
-1%
|
(63)
+2%
|
(54)
+14%
|
(47)
+13%
|
(42)
+9%
|
(37)
+12%
|
(38)
-2%
|
(37)
+3%
|
(37)
-1%
|
(39)
-5%
|
(40)
-2%
|
(38)
+5%
|
|
| EPS (Diluted) |
-8.84
N/A
|
-0.87
+90%
|
-0.23
+74%
|
-0.4
-74%
|
-0.6
-50%
|
-0.69
-15%
|
-0.53
+23%
|
-0.59
-11%
|
-0.67
-14%
|
-0.69
-3%
|
-1.6
-132%
|
-1.4
+13%
|
-1.5
-7%
|
-1.37
+9%
|
-1.18
+14%
|
-0.98
+17%
|
-1.13
-15%
|
-1.04
+8%
|
-0.93
+11%
|
-1.01
-9%
|
-1.18
-17%
|
-1.18
N/A
|
-1.29
-9%
|
-1.33
-3%
|
-1.34
-1%
|
-1.2
+10%
|
-1.15
+4%
|
-1.05
+9%
|
-1.12
-7%
|
-1.13
-1%
|
-1.12
+1%
|
-1.19
-6%
|
-1.23
-3%
|
-1.23
N/A
|
-1.2
+2%
|
-1.02
+15%
|
-0.89
+13%
|
-0.7
+21%
|
-0.58
+17%
|
-0.59
-2%
|
-58.25
-9 773%
|
-0.58
+99%
|
-60.65
-10 357%
|
-61.62
-2%
|
-58.75
+5%
|
|